C. Healy - Department of Oncology, Pfizer Inc

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 38 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide for Patients with Advanced Prostate Cancer and Changes in Specific DNA Repair Genes: a Plain Language Summary of the Results from the TALAPRO-2 Study

Karim Fizazi,Arun A Azad,Nobuaki Matsubara,Joan Carles,Andre P Fay,Ugo De Giorgi,Jae Young Joung, C,Eric Voog,Robert J Jones, Neal D Shore,Curtis Dunshee,Stefanie Zschäbitz,Jan Oldenburg,Dingwei Ye,Xun Lin,Cynthia G Healy,Nicola Di Santo,A Douglas Laird,Fabian Zohren,Neeraj Agarwal

Future oncology (London, England)no. 6 (2025): 637-652

Cited0Views0WOSBibtex

Exploration of Circulating Tumor Cell (CTC) Conversion and CTC0 As Prognostic Biomarkers for Efficacy in TALAPRO-2: Phase 3 Study of Talazoparib (TALA) + Enzalutamide (ENZA) Vs Placebo (PBO) + ENZA As First-Line (1L) Treatment in Patients (pts) with Metastatic Castration-Resistant Prostate Cancer (Mcrpc)

Steven Yip,Karim Fizazi,Douglas Laird,Nobuaki Matsubara,Arun Azad,Jae Young Joung,Peter C. C. Fong,Siska Van Bruwaene,Glenn Liu,Eric Voog,Cezary Szczylik,Jijumon Chelliserry,Cynthia G. Healy,Xun Lin,Neeraj Agarwal

Journal of Clinical Oncologyno. 16_suppl (2024): 5023-5023

Cited0Views0Bibtex

P103 Assessment of the Impact of Talazoparib Dose Reductions on the Efficacy of Combined Talazoparib and Enzalutamide Treatment in Patients with Metastatic Castrate Resistant Prostate Cancer (mcrpc) in the TALAPRO-2 (TP-2) Study

De Giorgi U.,Agarwal N.,Fizazi K.,Carles J.,Fay A.P.,Matsubara N.,Joung J.Y., Fong P.C.C.,Voog E.,Jones R.J., Shore N.,Zschäbitz S.,Oldenburg J., Xun L.,Healy C.G.,Deannuntis L., Kalac M., Azad A.

European Urology Open Science (2024): 124-125

Cited0Views0Bibtex

Utility of Ctdna Burden As a Prognostic Biomarker for Efficacy in TALAPRO-2: A Phase 3 Study of Talazoparib (TALA) + Enzalutamide (ENZA) Vs Placebo (PBO) + ENZA As First-Line (1L) Treatment in Patients (pts) with Metastatic Castration-Resistant Prostate Cancer (Mcrpc)

Arun Azad,Karim Fizazi,Douglas Laird,Nobuaki Matsubara,Ugo De Giorgi,Consuelo ButtIgliero,Lawrence Ivan Karsh,Jae Young Joung,Steven Yip,Stefanie Zschaebitz,Lee A. Albacker,Cynthia G. Healy,Xun Lin,Jijumon Chelliserry,Neeraj Agarwal

Journal of Clinical Oncologyno. 16_suppl (2024): 5020-5020

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn